Reduction of HDAC2 expression in human induced pluripotent stem cell derived neurons improves neuronal maturation, mitochondrial dynamics and cellular neurodegenerative disease phenotypes.

Harald Frankowski^{1,3*}, Fred Yeboah^{1,3,4*}, Bonnie J. Berry^{1,3*}, Chizuru Kinoshita^{1,3}, Michelle Lee^{1,3}, Kira Evitts^{1,3}, Joshua Davis^{1,3}, Yoshito Kinoshita^{1,3}, Richard S. Morrison² and Jessica E. Young^{1,3,#}

1. Department of Laboratory Medicine and Pathology

2. Department of Neurological Surgery

3. Institute for Stem Cell and Regenerative Medicine

4. Molecular and Cellular Biology Graduate Program

University of Washington, Seattle WA, USA

* These authors contributed equally to this work

#To whom correspondence should be addressed: jeyoung@uw.edu

Abstract: Histone deacetylase 2 (HDAC2) is a major HDAC protein in the adult brain and has been shown to regulate many neuronal genes. Aberrant expression of HDAC2 and subsequent dysregulation of neuronal gene expression is implicated in neurodegeneration and brain aging. Human induced pluripotent stem cell-derived neurons (hiPSC-Ns) are widely used models for studying neurodegenerative disease mechanisms, but the role of HDAC2 in hiPSC-N differentiation and maturation has not been explored. In this study, we show that levels of HDAC2 progressively decrease as hiPSCs are differentiated towards neurons. This suppression of HDAC2 inversely corresponds to an increase in neuron-specific isoforms of Endophilin-B1, a multifunctional protein involved in mitochondrial dynamics. Expression of neuron-specific isoforms of Endophilin-B1 is accompanied by concomitant expression of a neuron-specific alternative splicing factor, SRRM4. Manipulation of HDAC2 and Endophilin-B1 using lentiviral approaches shows that knock-down of HDAC2 or overexpression of a neuron-specific Endophilin-B1 isoform promotes mitochondrial elongation and protects against cytotoxic stress in hiPSC-Ns, while HDAC2 knock-down specifically influences genes regulating mitochondrial dynamics and synaptogenesis. Furthermore, HDAC2 knock-down promotes enhanced mitochondrial respiration and reduces levels of neurotoxic amyloid beta peptides. Collectively, our study demonstrates a role for HDAC2 in hiPSC-neuronal differentiation, highlights neuron-specific isoforms of Endophilin-B1 as a marker of differentiating hiPSC-Ns, and demonstrates that HDAC2 regulates key neuronal and mitochondrial pathways in hiPSC-Ns.

Keywords: hiPSCs, neuronal differentiation, histone deacetylase 2, endophilin-B1, mitochondria,

1. Introduction

Epigenetic dysregulation is a feature of many neurologic disorders, leading to aberrant gene expression that affects cellular metabolism and function[1]. Histone acetylation and deacetylation is a common epigenetic modification that can regulate gene expression by controlling chromatin structure. The extent of acetylation is regulated by balanced actions of histone acetyltransferases (HATs) and histone deacetylases (HDACs), regulates integral neuronal functions such as synaptic plasticity[2-6] and is important in neurodevelopment[7-9]. Imbalance of histone acetylation and deacetylation contributes to neuronal dysfunction in neurodegenerative disease[10] [11].

In particular, histone deacetylase 2 (HDAC2) is an abundant HDAC in the brain and has been shown to specifically regulate genes involved in cognition, learning, and memory [4, 5]. Dysregulation of HDAC2 has been implicated in neurodegenerative disorders including Alzheimer's Disease (AD)[3, 10, 12], where it may contribute to cognitive impairment[5]. Knock-down of HDAC2 leads to up-regulation of synaptic gene expression in primary murine neurons[6]. Recently, we demonstrated that HDAC2 is involved in regulation of neuronal mitochondrial dynamics via

the expression of Endophilin-B1 (*SH3GLB1*) in primary murine neurons. This work showed that increased HDAC2 sensitized neurons to mitochondrial dysfunction and cell death in neurodegenerative conditions[13].

Human induced pluripotent stem cells (hiPSC) are increasingly utilized for *in vitro* studies of neurologic disorders. Given that epigenetic dysregulation[14, 15], mitochondrial dysfunction[16-18], and synaptic dysfunction[19] are all implicated in multiple neurodevelopmental and neurodegenerative diseases, we investigated whether modulation of HDAC2 expression would impact neuronal maturation, mitochondrial dynamics and synaptic gene expression in neuronal cells derived from hiPSCs (hiPSC-Ns). Here we show that HDAC2 levels progressively decrease during neuronal differentiation and this inversely correlates with a natural increase in neuron-specific isoforms of Endophilin-B1 (Endo-B1b/c). We demonstrate that small-hairpin RNA (shRNA)-mediated knock-down of HDAC2 promotes Endo-B1b/c expression in hiPSC-derived cortical neurons, confirming that the regulation of Endo-B1b/c by HDAC2 in human neurons. We then dissect the roles of HDAC2 and Endo-B1b/c in human neurons using knock-down and overexpression experiments to demonstrate that both knock-down of HDAC2 and overexpression of Endo-B1c promote mitochondrial elongation and protect neurons from cytotoxic stress but only knock-down of HDAC2 influences the expression of genes involved mitochondrial gene expression and mitochondrial respiration. Finally, we show that reduction of HDAC2 in hiPSC-Ns decreases levels of Amyloid beta (A β), the cleavage product of the amyloid precursor protein (APP) implicated in neurotoxicity in AD. Our data confirms, in a human neuronal cell model, the role of HDAC2 in modulating neuronal synaptic gene expression, and also implicates several pathways in which HDAC2 modulates mitochondrial dynamics and physiology in hiPSC-Ns. HDAC2 inhibition may represent a therapeutic strategy for AD and other neurodegenerative disorders.

2. Results

2.1 Expression of HDAC2 and Endophilin-B1 (Endo-B1) isoforms in hiPSC-derived neurons

Our previous work demonstrates a role for HDAC2 in regulation of mitochondrial dynamics in primary mouse cortical neurons[13]. While class I HDACs, HDACs 1 and 2, are required for neuronal specification from neural progenitor cells[20] and control synapse function and maturation[8] in mice, HDAC2 expression and regulation of cellular processes in living, human neurons has not yet been examined. To begin to understand the role of HDAC2 in human neurons, we differentiated cortical neurons from well-characterized hiPSC lines[21-24] following our standard protocols[24-26] (Schematically depicted in Figure 1A). We harvested protein lysates from pluripotent stem cells (hiPSCs), neural progenitor cells that have not yet been directed to a neuronal lineage (NPCs), and neuronally differentiating NPC cultures at week 1, week 2 and week 3 time points. We observed that HDAC2 protein expression is present at all time points, with higher levels in neural progenitor cells that decline as neuronal differentiation proceeds (Figure 1B, C). Interestingly, endogenous expression of all class I HDACs (HDAC 1, 2, and 3) decreased with neuronal differentiation (Supplementary Fig. 1). This is consistent with work showing HDAC expression in neural progenitor cells in the developing mouse cortex[27]. Our previous work in mouse primary cortical neurons demonstrated that expression of HDAC2, but not other class I HDACs, negatively impacts the expression of Endophilin-B1 (Endo-B1), a multifunctional protein involved in mitochondrial dynamics[13]. In neurons, Endo-B1 is alternatively spliced yielding neuron-specific Endo-B1b and Endo-B1c as major isoforms relative to the ubiquitously expressed Endo-B1a[28]. Both of the neuron-specific isoforms are neuroprotective with Endo-B1c showing stronger activity in attenuating apoptotic cell death and causing mitochondrial elongation in mouse cortical neurons[28]. We therefore examined endogenous levels of Endo-B1 isoforms in neuronally differentiating cultures. As the cultures differentiate, we observed an increase in the neuron-specific isoforms of Endo-B1, which co-migrate on a western blot (designated as Endo-B1b/c), compared to the ubiquitous isoform Endo-B1a, which migrates at a lower molecular weight (Figure 1B,D). We next examined the expression of HDAC2 and Endo-B1 isoforms specifically in differentiating neuronal cells compared with hiPSCs and

NPCs. To this end, we enriched our cultures for neurons at each week of neuronal differentiation using magnetic bead sorting according to a modification of previously published protocols[29, 30]. We observed that HDAC2 mRNA expression is dynamically controlled as hiPSCs differentiate toward neuronal lineages (Figure 1E). Because the neuron-specific Endo-B1 protein isoforms cannot be separated on western blot, we designed primers to specifically detect Endo-B1a, Endo-B1b, and Endo-B1c mRNA isoforms and observed strong increases in Endo-B1b and Endo-B1c mRNA during neuronal differentiation with little change observed for Endo-B1a (Figure 1F). The neural-specific splicing factor SRRM4 has recently been implicated in alternative splicing of Endo-B1 pre-mRNA, favoring the generation of Endo-B1b and Endo-B1c isoforms over Endo-B1a[31]. We therefore analyzed SRRM4 levels during neuronal differentiation and observed that endogenous *SRRM4* is highly upregulated at week 1 of neuronal differentiation (Figure 1G), corresponding to the appearance of Endo-B1b and Endo-B1c isoforms at this stage (Figure 1B, F). While *SRRM4* levels decline towards the end of the three-week neuronal differentiation, *SRRM4* mRNA levels are still significantly increased compared with expression in NPCs and hiPSCs (Fig. 1G).

Figure 1. HDAC2 expression is dynamic during neuronal differentiation from hiPSCs and correlates with neuron-specific isoforms of Endophilin-B1, a protein that influences mitochondrial dynamics.

(A). Schematic of neuronal differentiation protocol from hiPSCs. Arrows indicate time points when NPCs or neurons were enriched by cell sorting. (B). Representative western blot analysis of endogenous HDAC2 and Endophilin-B1 levels in hiPSCs, NPCs, and during neuronal differentiation. Endo-B1a=ubiquitous isoform, Endo-B1b/c=neuron-specific isoforms. Note: Endo-B1b and Endo-B1c cannot be resolved on western blot[13, 28, 32] and are indicated as Endo-B1b/c. (C) Quantification of HDAC2 protein decreases during a three-week neuronal differentiation (N=3, *** $p < 0.001$ by one-way ANOVA with Tukey's multiple comparisons test). (D) Quantification of the ratio of Endo-B1b/c to Endo-B1a protein isoforms during neuronal differentiation (N=3, * $p < 0.05$ by one-way ANOVA with Tukey's multiple comparisons test). (E) Endogenous *HDAC2* mRNA harvested from hiPSCs, NPCs, and neuronally-enriched cultures harvested at 1, 2, and 3 weeks of differentiation. *HDAC2* mRNA expression increases during the first week of neuronal differentiation and then decreases substantially as neurons mature (N=3, **** $p < 0.0001$ by one-way ANOVA with Tukey's multiple comparisons test). (F) Quantification of *Endo-B1a*, *Endo-B1b*, and *Endo-B1c* mRNA isoforms in hiPSCs, NPCs, and neuronally-enriched cultures harvested at 1, 2, and 3 weeks of differentiation. *Endo-B1b* and *Endo-B1c* mRNA expression is significantly elevated during neuronal differentiation relative to the levels in hiPSCs and NPCs while little change was observed for *Endo-B1a* mRNA (N=3, **** $p < 0.0001$ by one-way ANOVA with Tukey's multiple comparisons test). (G) Quantification of *SRRM4* mRNA in hiPSCs, NPCs, and neuronally-enriched cultures harvested at 1, 2, and 3 weeks of differentiation. *SRRM4* is highly upregulated during the first two weeks of neuronal differentiation. While levels fall during the third week, *SRRM4* transcripts are still at significantly higher levels than in hiPSCs or NPCs (N=3, ** $p < 0.01$, **** $p < 0.0001$ by one-way ANOVA with Tukey's multiple comparisons test).

2.2 HDAC2 knock-down influences neuronal gene expression

Previous studies have implicated HDAC2 as a regulator of synaptic and cognitive gene expression[3] and shown that HDAC2 knock-down (HDAC KD) in mouse primary neurons leads to increases in synaptic gene expression[6]. Because we observed a natural decrease in HDAC2 levels as our hiPSC-Ns differentiate and mature, we tested whether an experimentally-evoked decrease of HDAC2 in differentiated hiPSC-Ns would further enhance expression of neuronal genes. In these experiments we differentiated neurons for three weeks and enriched by bead sorting. We transduced neurons with a lentivirus carrying a shRNA against HDAC2 and observed a strong decrease of HDAC2 mRNA (Figure 2A). In these HDAC2 KD cells we observed a significant increase in *TBR1* (Figure 2B), a transcription factor expressed in deep layer cortical neurons[33], suggesting that KD of HDAC2 promotes cortical neuron identity *in vitro*. In concordance with previous studies[6], we observed a significant increase in the mRNA expression of key synaptic genes: *SYNGR3*, *PSD95*, *SHANK2* and *SHANK3* (Figure 2C, D, E, F), suggesting that HDAC2 is a repressive regulator of synaptic gene expression in human neurons as well.

Figure 2. HDAC2 KD in hiPSC-derived neurons influences neuronal and synaptic gene expression

(A). Lentiviral transduction of hiPSC-Ns with an shRNA to HDAC2 significantly reduces HDAC2 mRNA. (B). Knock-down of HDAC2 (HDAC2 KD) increases mRNA of *TBR1*, a gene that influences cortical neuron identity. (C-F). HDAC2 KD increases expression of synaptic genes *PSD95* (C), *SYNGR3* (D), *SHANK2* (E), and *SHANK3* (F). HDAC2 KD vs. CTL neurons (Each dot represents the mean of 4-6 independent experiments, **p<0.01 by t-test, *p<0.05 by t-test).

2.3 HDAC2 knock-down upregulates the expression of *Endo-B1b/c* and *SRRM4*

The increasing *Endo-B1b/c* expression accompanied by declining HDAC2 expression during neuronal differentiation (Figure 1) suggests that the drop in HDAC2 may be promoting *Endo-B1b/c* expression. We next tested whether HDAC2 KD further increased neuronal isoforms of *Endo-B1*. We infected differentiated and enriched neurons with the HDAC2 shRNA lentivirus and observed a significant decrease in HDAC2 protein and increase in the *Endo-B1b/c* protein as compared to *Endo-B1a* (Figure 3A, B, C). We also observed a further increase in *SRRM4* mRNA (Figure 3D) and increase in the *Endo-B1b* and *Endo-B1c* mRNA splice isoforms (Figure 3E).

Figure 3. HDAC2 knock-down via shRNA further induces neuronal isoforms of Endo-B1 in hiPSC-derived neurons.

(A). Representative Western blot demonstrating HDAC2 KD after lentiviral infection and resulting induction of Endo-B1b/c isoforms at the protein level. (B-C). Quantification of HDAC2 protein and Endo-B1b/c:a isoform ratio in 3-week differentiated neurons transduced with HDAC2 shRNA (N=8, **p<0.01 by T-Test). (D). HDAC2 KD induces *SRRM4* mRNA expression. (E). HDAC2 KD induces *Endo-B1b* and *Endo-B1c* mRNA expression (Each dot represents the mean of 3-4 independent experiments, **p<0.01 by t-test).

2.4 HDAC2 and Endo-B1c expression influences mitochondrial length

Impaired mitochondrial dynamics and function is a hallmark of neurodegeneration in multiple models[34, 35]. Chemical pan-HDAC inhibitors have been shown to induce mitochondrial elongation[36]. Therefore, we first examined whether HDAC2 KD induces similar changes in mitochondrial shape in human neurons. We analyzed hiPSC-Ns stained with MitoTracker to measure mitochondrial length in the neurites and observed a significant increase in mitochondrial length in HDAC2 KD neurons compared to viral controls (Figure 4 A, B). Modulation of HDAC2 changes neuronal mitofusin 2 (MFN2) and mitochondrial fission factor (MFF) expression in mouse primary neurons[13]. Consistently, we observed that while HDAC2 KD only resulted in a small increase in *MFN2* mRNA, it caused a marked decrease in *MFF* mRNA (Figure 4 C, D). At the protein level, MFN2 protein levels were not different in HDAC2 KD neurons whereas MFF protein levels were significantly reduced (Figure 4E, F, G). Our results suggest that mitochondrial elongation apparent in HDAC2 KD neurons is mediated, at least in part, by a reduction in MFF levels.

Neuron-specific isoforms of Endo-B1 can also influence neuronal mitochondrial dynamics and previous work shows that Endo-B1c had the strongest effect on mitochondrial length in mouse neurons[28]. Therefore, we used a lentivirus to infect hiPSC-Ns with a construct that specifically overexpresses the Endo-B1c isoform and analyzed neuritic mitochondrial length. We document strong Endo-B1c overexpression (Figure 5A) and a significant increase in mitochondrial length in neurites (Figure 5 B, C). However, overexpression of Endo-B1c did not significantly affect *MFN2* or *MFF* mRNA expression (Figure 5 D,E). This is consistent with previous work showing no effect of Endo-B1 KD on these proteins[28] and suggests that Endo-B1b/c may affect fusion/fission protein activity in neuronal mitochondria rather than regulating gene expression of these fusion/fission proteins. Taken together, our results indicate that HDAC2 KD induces mitochondrial elongation in human neurons and suggest that it is mediated, at least in part, by increased Endo-B1b/c and decreased MFF expression as a result of HDAC2 KD.

Figure 4. Knock-down of HDAC2 in hiPSC-derived neurons leads to elongated mitochondria in neurites and influences expression of genes involved in mitochondrial dynamics.

(A). Representative image of elongated mitochondria visualized with Mitotracker in hiPSC-derived neurons with HDAC2 KD vs. CTL shRNA. (B). Quantification of mitochondrial length in neurites (N=4 independent Mitotracker experiments, 59 control mitochondria and 57 HDAC2 KD mitochondria, *** $p < 0.001$ by Mann-Whitney U test). (C) qRT-PCR analysis of Mitofusin 2 (MFN2) expression in HDAC2 KD (Each dot represents the mean of 4 independent experiments, * $p < 0.05$ by t-test). qRT-PCR analysis of Mitochondrial Fission Factor (MFF) expression in HDAC2 KD (Each dot represents the mean of 4 independent experiments, *** $p < 0.001$ by paired t-test). (D) Representative western blot analysis of MFN2 and MFF protein expression in CTL vs. HDAC2 KD conditions. MFN2 protein levels are unchanged in HDAC2 KD (N=6, NS=not significant by t-test). MFF protein levels are decreased in HDAC2 KD (N=6, *** $p < 0.001$ by t-test). Scale bar = 20μm.

Figure 5. Overexpression (OE) of Endophilin-B1c in hiPSC-derived neurons leads to elongated mitochondria but does not influence *MFN2*/*MFF* gene expression.

(A). mRNA quantification of Endo-B1c OE compared to a control OE vector (Each dot represents the mean of 4 independent experiments, **p < 0.01 by t-test). Representative western blot confirms overexpression of Endo-B1c protein. (B). Representative image of elongated mitochondria visualized with MitoTracker in hiPSC-derived neurons with Endo-B1c OE vs a control overexpression vector. (C). Quantification of mitochondrial length in neurites (N=4 independent MitoTracker experiments, 59 control mitochondria, and 62 Endo-B1c OE mitochondria, ****p < 0.0001 by Mann-Whitney U test). (D-E). qRT-PCR analysis of *MFN2* (D) and *MFF* (E) expression in Endo-B1c overexpressing neurons (Each dot represents the mean of 4 independent experiments, NS=not significant by t-test). Scale bar = 20 μm.

2.5 HDAC2 expression influences neuronal viability and mitochondrial respiration

Mitochondrial dynamics in cells contributes to viability and metabolism[37]. Endo-B1c has been shown to be anti-apoptotic in neuronal cells while promoting mitochondrial elongation[28], so we hypothesized that HDAC2 KD would also be neuroprotective due to the increased expression of Endo-B1c. We knocked down HDAC2 or overexpressed Endo-B1c in hiPSC-Ns and challenged them with the cytotoxic agent camptothecin, a DNA topoisomerase I inhibitor that induces p53-dependent neuronal apoptosis[38, 39]. We observed significant protection from camptothecin-induced cell death, as monitored based on caspase-3 activity, in both HDAC2 KD and Endo-B1c overexpression conditions (Figure 6), suggesting that HDAC2 KD can protect against neuronal cell death stimuli partly through elevated expression of neuron-specific Endo-B1 isoforms influencing mitochondrial elongation. Similarly, mitochondrial dynamics may influence respiration. Overexpression and knock-down of *MFN2* has been shown to increase and decrease mitochondrial respiration respectively[40] and in hiPSC-Ns knock-down of *MFN2* has been shown to decrease mitochondrial bioenergetics[41]. Inhibition of fission can also impact mitochondrial energy production[42]. We measured oxygen consumption rate (OCR), which is an indicator of mitochondrial respiratory activity, in HDAC2 KD

neurons using a Seahorse Bioscience XF96 analyzer. We observed a significant increase in basal and maximal OCR and in the spare respiratory capacity in HDAC2 KD neurons (Figure 7 A,B,C,D). We next tested whether overexpression of Endo-B1c had an effect on mitochondrial respiration but found no significant difference in any of the OCR parameters (Figure 7 E,F,G). An increase in mitochondrial biogenesis could explain the increase in respiration we observe in HDAC2 KD cells, however we did not detect a difference in mtDNA copy number in either HDAC2 knock-down neurons or Endo-B1c overexpressing neurons (Figure 7H). Together, these data suggest that decreasing HDAC2 levels in neurons may enhance mitochondrial respiration by regulating expression of genes that directly regulate metabolism.

Figure 6. HDAC2 KD and OE of Endo-B1c in hiPSC-derived neurons is protective against neuronal stress.

hiPSC-derived neurons were treated for 24 hours with 20 μ M camptothecin. Cell death was quantified by measuring caspase-3 activity. Each dot represents a technical replicate of 3-4 independent experiments. Analysis compares all groups to the CTL/untreated bar (white) using a one-way ANOVA with Tukey post-hoc multiple comparisons; ** $p < 0.01$; * $p < 0.05$.

Figure 7. HDAC2 KD but not OE of EndophilinB1-c improves mitochondrial respiration in hiPSC-derived neurons.

(A-C). Plots of individual Seahorse assays measuring the oxygen consumption rate (OCR) of hiPSC-Ns with HDAC2 KD compared to a control virus. (D). Compilation of the three independent Seahorse assays (shown in A-C) shows significant increases in basal respiration, maximum respiration (Max resp.), and spare capacity. Each dot represents a technical replicate within each independent assay and data is analyzed using a one-way ANOVA with Tukey post-hoc multiple comparisons; * $p < 0.05$; ** $p < 0.01$; **** $p < 0.0001$. (E-F). Plots of individual Seahorse assays of hiPSC-Ns with EndoB1-c overexpression compared to a control virus. (G). Compilation of the two independent Seahorse assays (shown in E-F) shows no significant changes in basal respiration, maximum respiration (Max resp.), proton leak, or spare capacity. Each dot represents a technical replicate within each independent assay and data is analyzed using a one-way ANOVA with Tukey post-hoc multiple comparisons; NS=non-significant. (H). Analysis of mitochondrial DNA copy number in hiPSC-Ns with HDAC2 KD or Endo-B1c OE. No significant difference was found in mitochondrial copy number in either condition when compared to a control virus. NS=non-significant by t-test.

2.6 HDAC2 knock-down reduces amyloid beta ($A\beta$) 1-40 and 1-42 peptides

Previous studies have demonstrated that HDAC2 expression is specifically increased in neurons in the AD brain using immunohistochemical approaches and HDAC inhibition may have therapeutic potential for neurodegenerative disease[3, 43]. One of the neuropathological hallmarks of AD is senile plaques comprised of $A\beta$ peptides generated by amyloidogenic cleavage of APP. $A\beta$ peptides can be of various lengths with $A\beta$ 1-40 being the most abundant and $A\beta$ 1-42 being more neurotoxic[44]. We tested whether HDAC2 KD influenced $A\beta$ peptides secreted by hiPSC-Ns into the culture media. hiPSC-Ns from AD patients as well as from non-demented controls show detectable levels of $A\beta$ [23, 24, 29] and levels of these peptides can be reduced by treatment with various small molecules[24, 45, 46]. We infected wild-type (WT) hiPSC-Ns and hiPSC-Ns derived from a patient with a duplication of APP (APP^{DP})[47], which has been used and characterized in other studies[29], with either the control or HDAC2 KD lentivirus. We measured the levels of secreted $A\beta$ peptides in the culture media and observed that in both WT and APP^{DP} hiPSC-Ns, HDAC2 KD reduced the levels of both $A\beta$ 1-40 and $A\beta$ 1-42. We see a similar magnitude in $A\beta$ peptide reduction from both the control and the APP^{DP} cell lines, suggesting that HDAC2 does not impact this pathway differently based on the presence or absence of a familial AD mutation and thus may be beneficial in several treatment scenarios.

Figure 8. Knock-down of HDAC2 reduces $A\beta$ peptides in hiPSC-Ns. $A\beta$ peptides (1-40 and 1-42) secreted into the media from both WT and APP^{DP} hiPSC-Ns were reduced under HDAC2 knock-down conditions. The data represents two independent differentiations, CTL vs. HDAC2 KD analyzed by t-test**p<0.01; *p<0.05.

3. Discussion

Acetylation and deacetylation of histones is critical for regulating gene expression and is essential to normal neuronal development and function with dysregulated acetylation/deacetylation contributing to development of neurodegenerative conditions. Expression of the epigenetic regulator HDAC2 is altered in neurodegenerative diseases such as Alzheimer's disease and this may influence expression of genes related to cognition[3]. Previously, we demonstrated that HDAC2 regulates expression of neuron-specific isoforms of Endo-B1, a protein that confers neuroprotection and promotes mitochondrial elongation, uncovering a novel role of HDAC2 in regulation of mitochondrial function[13]. In this study, we sought to understand how HDAC2 expression influences hiPSC-N maturation and mitochondrial size and function. We first assessed HDAC2 expression during neuronal differentiation from hiPSCs and demonstrated progressively decreasing levels of HDAC2 mRNA and protein with time. HDAC2 is a class I HDAC that is important for neurodevelopment[48]. Studies in olfactory receptor neurons in the olfactory epithelium in mice showed that HDAC2 is highly expressed in early post-mitotic neurons, but not glia, and is down-regulated during neuronal maturation[7, 49]. Other studies show that HDAC2 expression is important for silencing neural progenitor transcripts during adult neurogenesis in the mouse[50]. Together, these studies indicate that HDAC2 expression is dynamic in differentiating and maturing neurons. In our study, we detect HDAC2 expression at mRNA and protein levels at all stages of the cells we studied (pluripotent-hiPSCs, neural progenitor cells-NPCs, and

differentiating neurons). Interestingly, HDAC2 levels appear to increase one week after neuronal induction from NPCs and then decrease as neurons further differentiate and mature, however there is still measurable expression of HDAC2 in differentiated neurons on par with the level in hiPSCs. Future work looking at expression of other class I HDACs in differentiating neurons and class I HDACs, including HDAC2, in differentiating glial cells will be important in determining the complex roles these HDACs play in human neural development.

Because we noted a decline in HDAC2 levels as hiPSC-Ns matured during neuronal differentiation, we hypothesized that the decline in HDAC2 levels may facilitate expression of genes that support neuronal function. Previous work in mouse primary neurons showed that knock-down of HDAC2 induces expression of synaptic genes by directly regulating histone acetylation at the promoter[6], which is complementary to data suggesting that upregulation of HDAC2 negatively affects expression of genes involved in cognition[3]. Consistent with these results, using an shRNA approach to further decrease HDAC2 levels in our differentiated hiPSC-Ns we revealed that decreased HDAC2 levels lead to increased expression of pre- and post-synaptic genes. Although our results cannot rule out an indirect effect of HDAC2 on genes we did not measure, these previous and current findings suggest that decreasing HDAC2 levels in neurons, including human neurons, may promote neuronal maturation and function and that lowering HDAC2 levels may be a strategy to restore normal function in neurologic disorders.

Previously we reported that HDAC2 regulates expression of Endo-B1, a multifunctional protein involved in mitochondrial dynamics. Specifically, we showed that decreasing HDAC2 levels in mouse neurons inversely elevates neuron-specific and neuroprotective Endo-B1 isoforms[13]. Neuron-specific isoforms of Endo-B1 promote neuronal survival and their expression in the brain is reduced in mouse models and human models of AD and mouse models of stroke [28, 32]. We observed an increase in neuron-specific isoforms, Endo-B1b/c, as our human neurons differentiate and mature, consistent with the decreasing HDAC2 expression concurrently observed. Prompted by previous reports implicating the neuron-specific splicing factor SRRM4 in the alternative splicing of Endo-B1 (*SH3GLB1*)[31, 51], we examined whether changes in SRRM4 expression correlate with the appearance of Endo-B1b/c isoforms. We found that *SRRM4* mRNA expression is indeed induced upon neuronal differentiation and further demonstrated that *SRRM4* mRNA is upregulated by HDAC2 KD in differentiated neurons, suggesting that *SRRM4* gene expression may be negatively regulated by HDAC2 in human neurons. Thus, our data suggest that lowering HDAC2 levels may promote expression of *SRRM4* facilitating neuron-specific splicing of Endo-B1, which in turn can allow the resulting neuron-specific Endo-B1b/c isoforms to promote mitochondrial elongation. As expected, overexpression of Endo-B1c in hiPSC-Ns had a significant effect on mitochondrial elongation as well.

While knock-down of HDAC2 increases mitochondrial elongation likely through the induction of Endo-B1c, we also examined expression of MFN2 and MFF, molecules that promote fusion and fission of mitochondria, respectively. Our previous work showed that HDAC2 overexpression increases MFF expression while decreasing MFN2 expression in mouse neurons[13]. Consistently, HDAC2 KD in differentiated hiPSC-Ns conversely induced a significant decrease in *MFF* mRNA and protein although no significant effect was observed for MFN2. Separately, we confirmed that Endo-B1c overexpression has no effect on MFF or MFN2 mRNA expression, ruling out any transcriptional activity of Endo-B1c, consistent with the reported cytosolic and/or mitochondrial localization of Endo-B1[52]. Endo-B1c may thus have a more physical role in elongation of mitochondria. Indeed, recent work shows that Endo-B1 can regulate the mitochondrial inner membrane through an interaction with prohibitin-2[53]. Taken together, our data suggests that modulation of HDAC2 in hiPSC-Ns influences mitochondrial dynamics, in part, through regulation of the expression of fusion and fission proteins, which includes alternative splicing-regulated production of the net fusion-promoting Endo-B1b/c isoforms (with the assistance of concomitantly regulated expression of *SRRM4*) and transcriptional regulation of *MFF* gene.

In addition to mitochondrial elongation, increased mitochondrial biogenesis is reported in terminally differentiated mouse cortical neurons[54]. In human pluripotent stem cell differentiations, cells undergo a shift from glycolysis in neural progenitors to oxidative phosphorylation in differentiating neurons[55]. We therefore decided to examine the effects of HDAC2 KD and the resulting upregulation of Endo-B1b/c on mitochondrial respiration and biogenesis in hiPSC-Ns. Analyses using a Seahorse Flux analyzer demonstrated that HDAC2 KD evokes a significant increase in OCRs representing the basal respiration, the maximal respiration and the spare respiratory capacity. This suggests that lowering levels of HDAC2 improves multiple aspects of mitochondrial physiology towards, for instance, more neuronally mature and thus more oxidative modes of metabolism and augmented bioenergetic capacity to confer increased resistance to stress. Interestingly, a similar action of HDAC has been reported in HL-1 cells derived from mouse atrial cardiac muscle, where HDAC inhibition with a class I HDAC-specific inhibitor, MPT0E014, improves mitochondrial OCR following TNF-alpha treatment to model heart failure[56]. These findings suggest that reducing HDAC may be a conserved process that could benefit mitochondrial bioenergetics across many different tissues. Interestingly, overexpression of Endo-B1c did not significantly affect these respiratory parameters. This indicates that the improved respiratory function in HDAC2 KD neurons is not solely a result of increased mitochondrial length. The absence of an increase in oxidative phosphorylation despite mitochondrial elongation induced by Endo-B1c overexpression suggests that these two functions are not always dependent on each other. Indeed, a carboxy-terminal truncation of MFN2 has been shown abrogate its mitochondrial fusion capacity but was still able to induce an increase in mitochondrial membrane potential and stimulate glucose oxidation[40]. Finally, we also tested whether the changes in mitochondrial respiration in HDAC2 KD cells were due to increases in mitochondrial biogenesis, however we did not see significant differences in mtDNA copy number in either HDAC2 KD or Endo-B1c OE cells.

Because decreased HDAC2 levels induce Endo-B1c expression, which is known to be anti-apoptotic in neurons, we tested whether HDAC2 KD or Endo-B1c overexpression would protect hiPSC-Ns against a neurotoxic insult. Both HDAC2 KD and Endo-B1c overexpression significantly reduced caspase-3 activity induced by camptothecin treatment. This data suggests that lowering HDAC2 levels, either by genetic or pharmacologic means, may be a viable strategy in maintaining or restoring viability of human neurons during disease conditions and that forced expression of Endo-B1c could substitute such HDAC2 manipulation.

Mitochondrial and synaptic dysfunction are implicated in neurodegenerative disease pathogenesis and strategies to improve these pathways can be considered for novel therapeutic development. Indeed, HDAC inhibition has been suggested as a possible therapeutic pathways for neurodegeneration[43]. We tested whether HDAC2 knock-down could improve a cellular phenotype related to AD pathology, A β secretion into neuronal culture media. In both control and APP^{DP} neurons, knock-down of HDAC2 significantly reduced the levels of secreted A β 1-40 and A β 1-42 peptides. These data suggest that further investigation into HDAC inhibition, specifically HDAC2 inhibition, as a therapeutic strategy for AD is warranted.

In this study, we report a role for endogenous HDAC2 during human neuronal differentiation. Our data suggest a repressive regulation of the neuron-specific splicing factor SRRM4 by HDAC2 and highlights Endo-B1b/c isoforms as novel functional contributors to and markers of human cortical neuronal differentiation. Using lentiviral knock-down and overexpression approaches we further confirm previous work in mice demonstrating that HDAC2 acts repressively on synaptic gene expression and we solidify the finding that HDAC2 regulates genes involved in mitochondrial bioenergetics-and dynamics by showing, for the first time, this effect in hiPSC-Ns. Finally, we show a significant effect of HDAC2 on neuronal mitochondrial respiration and neuroprotection. Our data supports the idea that manipulation of HDAC2 may be beneficial in the treatment of neurological diseases.

4. Materials and Methods

4.1 Cell culture and hiPSC neuronal differentiation

These experiments represent data obtained from two well characterized control hiPSCs lines (CV and WTC11)[57, 58]. The data showing reduction of A β in FAD cells was obtained from a cell line with an APP duplication[29]. The CV line was generated at the University of California, San Diego and was transferred to Dr. Young via a Material Transfer Agreement. The APP^{DP} cell lines was generated at the University of California, San Diego and was transferred to Dr. Young via a Material Transfer Agreement. The WTC11 line was obtained from Dr. Carol Ware at the University of Washington's Ellison Stem Cell Core. hiPSCs were cultured under feeder-free conditions and differentiated to neural progenitor cells (NPCs) following published protocols utilizing dual SMAD inhibition and after 12 days NPCs were purified using sorting for CD184+/CD24+ populations as previously described[30, 59, 60]. Neuronal differentiation of NPCs to cortical neurons was performed as we have previously published[23, 25, 26]. Briefly, NPCs were seeded at 10x10⁶ per 10cm plate and differentiated for three weeks in the presence of GDNF (PeproTech 20 ng/ml), BDNF (PeproTech 20 ng/ml) and dbcAMP (Sigma 250ug/ml). To analyze cultures enriched in neurons, differentiated cultures were dissociated into a single cell suspension using Accutase and incubated with antibodies against CD184-PE and CD44-PE. Anti-PE magnetic beads (iMag, BD Biosciences) were added and complexes were pulled down. The neuronally enriched supernatant was re-plated in a modification of the sorting protocol published by Yuan et al.[30] and used in our previous publications[24-26].

4.2 Lentivirus treatment

Lentiviruses carrying a control shRNA, HDAC2 shRNA, GFP or Endo-B1c plasmids were generated as previously described[3, 13]. For all lentivirus treatments, neurons were differentiated for three weeks and enriched by bead sorting. Four days after enrichment, viruses were added to the cultures and left for three days. Cells were further maintained in virus-free medium for 2 weeks and then harvested or used for assays.

4.3 RNA purification and qPCR analysis

Total RNA was purified from 2*10E5 cells using TRIzol (Life Technologies) followed by 1st strand cDNA synthesized using the iScript kit (Biorad). Between 5 and 10ng of cDNA were used in a 4ul reaction using POWEU SYBR qPCR mix (Life Technologies). All primer-sets were run in technical triplicates. Expression was calculated using the 2⁻ $\Delta\Delta$ Ct method and genes of interest were normalized to RPL27. qPCR primers designed over exon-exon boundaries using Primer-Blast are below:

hHDAC2	TGAGATTCCCAATGAGTTGCCA	TACTGACATCTGGTCAGACA
hMFN2	CACCCTGATGCAGACGGAAA	TCCATGTACTCGGGCTCTGA
hMFF	CAGCTTCACTAAGACGACAGATAA	TTACCTCTAGCGGCGAAACC
hPSD95	CTCAGGGTCAACGACAGCAT	AAGCCAAGACCTTTAGGCCC
hRPL27	TGAGATTCCCAATGAGTTGCCA	TACTGACATCTGGTCAGACA

hSH3GLB1 isoform c	CATGTAAAATGGCTGAAGATTGG	TGGGCATGTGTACTGCTGAT
hSHANK2	CTGGCGAGCTGGGGTGATTA	TCAATGGGTGTGTCAGCTTTG
hSHANK3	CCTCACCTCACACAGCGATT	CCACCGACTCGAGATACTGC
hSYNGR3	CGTCCTGGGTGTTCTCCATC	CTGCTGATTTGCTGGAAGCG
hSRMM4	ATAGCCCATCGCCTGTCAAG	GCCGGCTTCGAGATTGTTTC

4.4 Western blot analysis

2x10⁵ cells were lysed in 50 µl RIPA buffer and protein amount was assessed using BCA assay kit (Thermo Scientific). Between 3 and 10 µg of total protein were loaded on to a 4-15% gradient TGX gel (Bio-Rad) and transferred on to a PVDF membrane (Bio-Rad), which was then treated with 0.4% paraformaldehyde for 30 min to fix proteins. Following blocking with 5% nonfat dry milk, 0.1% Tween 20 and 0.05% thimerosal, membrane was incubated with the primary antibody diluted in 5% bovine serum albumin, 0.1% Tween 20, 0.05% thimerosal and 0.2% NaN₃ overnight at 4°C, followed by horse radish peroxidase-conjugated secondary antibody (1:2000, GE Healthcare) diluted in the blocking buffer. Membrane was then developed using Clarity Western ECL substrate (Bio-Rad) and exposed to Hyperfilm ECL (GE Healthcare). Films were digitally scanned, and band intensity was quantitated using ImageJ and normalized against β-actin.

Antibodies

HDAC2	Sigma H2663 (2 mg/ml)	1:5000
Bif-1/Endophilin-B1(30A882.1.1)	Novus #NBP2-24733 (0.5 mg/ml)	1:1000
MFN2	Abcam #ab124773 (1.549 mg/ml)	1:2000
MFF	Proteintech #17090-1-AP (45 µg/150 µl)	1:2000
Actin	Sigma A5441	1:2500

4.5 Mitochondrial length analysis

Mitochondria were stained with MitoTracker Red (Invitrogen M7513) following manufacturer's instructions, and pictures of at least three independent fields per sample were taken on a NIKON A1R confocal system using a 60x objective. Mitochondrial length was quantified by a blinded observer using ImageJ as we have previously described[28].

4.6 Caspase 3 analysis

Neurons were cultured in a 96 well plate, in replicates, at a concentration of 2 x 10⁵ cells/well, treated with lentiviruses as indicated above (4.2) and were then treated for 24hrs with 20 µM camptothecin or with vehicle (DMSO) alone. Cells were then lysed and a caspase-3 assay was performed according to the manufacturer's protocol (EnzChek caspase-3 Assay, Invitrogen). The intensity of fluorescence was analyzed using an EnVizion plate reader.

4.7 Seahorse analysis

Neurons were plated in a Matrigel-coated 96 well Seahorse plate at a density of 2 x 10⁵ cells/well and transduced with lentivirus as described above. The MitoStress protocol in the Seahorse flux analyzer was performed two weeks later.

An hour before the assay, the culture media was replaced with base media (Agilent Seahorse XF base medium, 103334-100) supplemented with 25 mM glucose and 1 mM Sodium pyruvate (Gibco - 11360070). Substrates and select inhibitors of the different complexes were injected during the measurement to achieve final concentrations of oligomycin (2.5 μ M), FCCP (1 μ M), rotenone (2.5 μ M) and antimycin (2.5 μ M). The oxygen consumption rate (OCR) values were then normalized with readings from Hoechst staining (Sigma-Aldrich HO33342), which corresponded to the number of cells in the well.

4.8 Mitochondrial DNA copy number analysis

Genomic DNA was prepared from samples in TRIzol (Life Technologies) that had previously been used to extract RNA according to manufacturer's protocol. 10 ng of genomic DNA were used per qPCR reaction and each sample was assessed in triplicate for mitochondrial ND1 (F: CCCTAAAACCCGCCACATCT, R: GAGCGATGGTGAGAGCTAAGGT) and nuclear LPL (F: CGAGTCGTCTTTCTCCTGATGAT, R: TTCTGGATTCCAATGCTTCGA) genes. Nuclear DNA-normalized, relative mitochondrial DNA content is provided by $2 \times 2^{\Delta CT}$ where $\Delta CT = (\text{nucDNA CT} - \text{mtDNA CT})$.

4.9 A β 1-40 and 1-42 analysis

A β peptides were measured as previously described[24]. Briefly neurons were differentiated as described above in 4.1 and plated at 200,000 cells per well. The neurons were treated with lentiviruses as described above in 4.2. Medium was harvested to measure secreted A β peptides, media was run on an A β V-plex ELISA plate (Meso Scale Discovery) per manufacturers instructions.

4.10 Statistical analysis

Data represents two individual cell lines performed in biological and technical replicates. All data was analyzed using GraphPad Prism software v. 8 (GraphPad Software, Inc., La Jolla, USA). For each data set, data was analyzed for normal distribution using the Shapiro-Wilk Test. Normally distributed data were analyzed using parametric statistical tests. For comparisons of more than two groups one-way ANOVA analysis was used with Tukey's post-hoc multiple comparisons test. For data in two groups two-tailed T-Tests were used. For non-normally distributed data, non-parametric tests were used. For non-normal data comparing two groups, the Mann-Whitney U test was used. Definition of replicates and all statistical tests used and p-values are reported in the figure legends.

Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Figure S1: Western Blots

Author Contributions: Conceptualization of project: RSM, HF, JEY. Methodology: FY, HF, BJB, CK, ML, KE, JD. Data Analysis: FY, HF, BJB, JEY. Writing-original draft: JEY, HF, BJB, YK; Writing-review and editing: BJB, FY, KE, YK. Funding acquisition: JEY, RSM, FY.

Funding: This work was supported by NIH grants AG059841 to JEY, NS35533 and NS056031 to RSM, an ISCRM Scholars Fellowship to FY, and a generous gift from the Ellison Foundation (to UW).

Acknowledgments: We wish to acknowledge our colleague, friend and mentor, Dr. Richard S. Morrison who passed away during the preparation of this manuscript. He was a great scientist, a wonderful mentor, and a dear friend. We also acknowledge all the members of the Young Lab for helpful discussion and Melissa Barker-Haliski for critical reading and comments on the manuscript.

Conflicts of Interest: The authors declare that they have no conflict of interest

References

1. Lardenoije, R.; Iatrou, A.; Kenis, G.; Kompotis, K.; Steinbusch, H. W.; Mastroeni, D.; Coleman, P.; Lemere, C. A.; Hof, P. R.; van den Hove, D. L.; Rutten, B. P., The epigenetics of aging and neurodegeneration. *Prog Neurobiol* **2015**, 131, 21-64.
2. Graff, J.; Joseph, N. F.; Horn, M. E.; Samiei, A.; Meng, J.; Seo, J.; Rei, D.; Bero, A. W.; Phan, T. X.; Wagner, F.; Holson, E.; Xu, J.; Sun, J.; Neve, R. L.; Mach, R. H.; Haggarty, S. J.; Tsai, L. H., Epigenetic priming of memory updating during reconsolidation to attenuate remote fear memories. *Cell* **2014**, 156, (1-2), 261-76.
3. Graff, J.; Rei, D.; Guan, J. S.; Wang, W. Y.; Seo, J.; Hennig, K. M.; Nieland, T. J.; Fass, D. M.; Kao, P. F.; Kahn, M.; Su, S. C.; Samiei, A.; Joseph, N.; Haggarty, S. J.; Delalle, I.; Tsai, L. H., An epigenetic blockade of cognitive functions in the neurodegenerating brain. *Nature* **2012**, 483, (7388), 222-6.
4. Guan, J. S.; Haggarty, S. J.; Giacometti, E.; Dannenberg, J. H.; Joseph, N.; Gao, J.; Nieland, T. J.; Zhou, Y.; Wang, X.; Mazitschek, R.; Bradner, J. E.; DePinho, R. A.; Jaenisch, R.; Tsai, L. H., HDAC2 negatively regulates memory formation and synaptic plasticity. *Nature* **2009**, 459, (7243), 55-60.
5. Penney, J.; Tsai, L. H., Histone deacetylases in memory and cognition. *Sci Signal* **2014**, 7, (355), re12.
6. Yamakawa, H.; Cheng, J.; Penney, J.; Gao, F.; Rueda, R.; Wang, J.; Yamakawa, S.; Kritskiy, O.; Gjoneska, E.; Tsai, L. H., The Transcription Factor Sp3 Cooperates with HDAC2 to Regulate Synaptic Function and Plasticity in Neurons. *Cell reports* **2017**, 20, (6), 1319-1334.
7. MacDonald, J. L.; Roskams, A. J., Histone deacetylases 1 and 2 are expressed at distinct stages of neuro-glial development. *Dev Dyn* **2008**, 237, (8), 2256-67.
8. Akhtar, M. W.; Raingo, J.; Nelson, E. D.; Montgomery, R. L.; Olson, E. N.; Kavalali, E. T.; Monteggia, L. M., Histone deacetylases 1 and 2 form a developmental switch that controls excitatory synapse maturation and function. *J Neurosci* **2009**, 29, (25), 8288-97.
9. Jaworska, J.; Ziemka-Nalecz, M.; Zalewska, T., Histone deacetylases 1 and 2 are required for brain development. *Int J Dev Biol* **2015**, 59, (4-6), 171-7.
10. Panikker, P.; Xu, S. J.; Zhang, H.; Sarthi, J.; Beaver, M.; Sheth, A.; Akhter, S.; Elefant, F., Restoring Tip60 HAT/HDAC2 Balance in the Neurodegenerative Brain Relieves Epigenetic Transcriptional Repression and Reinstates Cognition. *J Neurosci* **2018**, 38, (19), 4569-4583.
11. Bonnaud, E. M.; Suberbielle, E.; Malnou, C. E., Histone acetylation in neuronal (dys)function. *Biomol Concepts* **2016**, 7, (2), 103-16.
12. Mahady, L.; Nadeem, M.; Malek-Ahmadi, M.; Chen, K.; Perez, S. E.; Mufson, E. J., HDAC2 dysregulation in the nucleus basalis of Meynert during the progression of Alzheimer's disease. *Neuropathol Appl Neurobiol* **2019**, 45, (4), 380-397.
13. Wang, D. B.; Kinoshita, C.; Kinoshita, Y.; Sopher, B. L.; Uo, T.; Lee, R. J.; Kim, J. K.; Murphy, S. P.; Dirk Keene, C.; Garden, G. A.; Morrison, R. S., Neuronal susceptibility to beta-amyloid toxicity and ischemic injury involves histone deacetylase-2 regulation of endophilin-B1. *Brain Pathol* **2019**, 29, (2), 164-175.
14. Li, P.; Marshall, L.; Oh, G.; Jakubowski, J. L.; Groot, D.; He, Y.; Wang, T.; Petronis, A.; Labrie, V., Epigenetic dysregulation of enhancers in neurons is associated with Alzheimer's disease pathology and cognitive symptoms. *Nat Commun* **2019**, 10, (1), 2246.

15. Zusso, M.; Barbierato, M.; Facci, L.; Skaper, S. D.; Giusti, P., Neuroepigenetics and Alzheimer's Disease: An Update. *J Alzheimers Dis* **2018**, 64, (3), 671-688. 647 648
16. Smith, M. A.; Perry, G.; Richey, P. L.; Sayre, L. M.; Anderson, V. E.; Beal, M. F.; Kowall, N., Oxidative damage in Alzheimer's. *Nature* **1996**, 382, (6587), 120-1. 649 650
17. Manczak, M.; Calkins, M. J.; Reddy, P. H., Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage. *Hum Mol Genet* **2011**, 20, (13), 2495-509. 651 652 653
18. Cai, Q.; Tammineni, P., Mitochondrial Aspects of Synaptic Dysfunction in Alzheimer's Disease. *J Alzheimers Dis* **2017**, 57, (4), 1087-1103. 654 655
19. Li, K.; Wei, Q.; Liu, F. F.; Hu, F.; Xie, A. J.; Zhu, L. Q.; Liu, D., Synaptic Dysfunction in Alzheimer's Disease: Abeta, Tau, and Epigenetic Alterations. *Mol Neurobiol* **2018**, 55, (4), 3021-3032. 656 657
20. Montgomery, R. L.; Hsieh, J.; Barbosa, A. C.; Richardson, J. A.; Olson, E. N., Histone deacetylases 1 and 2 control the progression of neural precursors to neurons during brain development. *Proc Natl Acad Sci U S A* **2009**, 106, (19), 7876-81. 658 659 660
21. Gore, A.; Li, Z.; Fung, H. L.; Young, J. E.; Agarwal, S.; Antosiewicz-Bourget, J.; Canto, I.; Giorgetti, A.; Israel, M. A.; Kiskinis, E.; Lee, J. H.; Loh, Y. H.; Manos, P. D.; Montserrat, N.; Panopoulos, A. D.; Ruiz, S.; Wilbert, M. L.; Yu, J.; Kirkness, E. F.; Izpisua Belmonte, J. C.; Rossi, D. J.; Thomson, J. A.; Eggan, K.; Daley, G. Q.; Goldstein, L. S.; Zhang, K., Somatic coding mutations in human induced pluripotent stem cells. *Nature* **2011**, 471, (7336), 63-7. 661 662 663 664 665
22. Woodruff, G.; Young, J. E.; Martinez, F. J.; Buen, F.; Gore, A.; Kinaga, J.; Li, Z.; Yuan, S. H.; Zhang, K.; Goldstein, L. S., The presenilin-1 DeltaE9 mutation results in reduced gamma-secretase activity, but not total loss of PS1 function, in isogenic human stem cells. *Cell reports* **2013**, 5, (4), 974-85. 666 667 668
23. Young, J. E.; Boulanger-Weill, J.; Williams, D. A.; Woodruff, G.; Buen, F.; Revilla, A. C.; Herrera, C.; Israel, M. A.; Yuan, S. H.; Edland, S. D.; Goldstein, L. S., Elucidating Molecular Phenotypes Caused by the SORL1 Alzheimer's Disease Genetic Risk Factor Using Human Induced Pluripotent Stem Cells. *Cell Stem Cell* **2015**, 16, (4), 373-85. 669 670 671 672
24. Young, J. E.; Fong, L. K.; Frankowski, H.; Petsko, G. A.; Small, S. A.; Goldstein, L. S. B., Stabilizing the Retromer Complex in a Human Stem Cell Model of Alzheimer's Disease Reduces TAU Phosphorylation Independently of Amyloid Precursor Protein. *Stem Cell Reports* **2018**, 10, (3), 1046-1058. 673 674 675 676
25. Knupp, A.; Mishra, S.; Martinez, R.; Bragg, J. E.; Szabo, M.; Kinoshita, C.; Hailey, D. W.; Small, S. A.; Jayadev, S.; Young, J. E., Depletion of the AD Risk Gene SORL1 Selectively Impairs Neuronal Endosomal Traffic Independent of Amyloidogenic APP Processing. *Cell reports* **2020**, 31, (9), 107719. 677 678 679 680
26. Rose, S. E.; Frankowski, H.; Knupp, A.; Berry, B. J.; Martinez, R.; Dinh, S. Q.; Bruner, L. T.; Willis, S. L.; Crane, P. K.; Larson, E. B.; Grabowski, T.; Darvas, M.; Keene, C. D.; Young, J. E., Leptomeninges-Derived Induced Pluripotent Stem Cells and Directly Converted Neurons From Autopsy Cases With Varying Neuropathologic Backgrounds. *J Neuropathol Exp Neurol* **2018**. 681 682 683 684
27. Tang, T.; Zhang, Y.; Wang, Y.; Cai, Z.; Lu, Z.; Li, L.; Huang, R.; Hagelkruys, A.; Matthias, P.; Zhang, H.; Seiser, C.; Xie, Y., HDAC1 and HDAC2 Regulate Intermediate Progenitor Positioning to Safeguard Neocortical Development. *Neuron* **2019**, 101, (6), 1117-1133 e5. 685 686 687

28. Wang, D. B.; Uo, T.; Kinoshita, C.; Sopher, B. L.; Lee, R. J.; Murphy, S. P.; Kinoshita, Y.; Garden, G. A.; Wang, H. G.; Morrison, R. S., Bax interacting factor-1 promotes survival and mitochondrial elongation in neurons. *J Neurosci* **2014**, 34, (7), 2674-83.
29. Israel, M. A.; Yuan, S. H.; Bardy, C.; Reyna, S. M.; Mu, Y.; Herrera, C.; Hefferan, M. P.; Van Gorp, S.; Nazor, K. L.; Boscolo, F. S.; Carson, C. T.; Laurent, L. C.; Marsala, M.; Gage, F. H.; Remes, A. M.; Koo, E. H.; Goldstein, L. S., Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. *Nature* **2012**, 482, (7384), 216-20.
30. Yuan, S. H.; Martin, J.; Elia, J.; Flippin, J.; Paramban, R. I.; Hefferan, M. P.; Vidal, J. G.; Mu, Y.; Killian, R. L.; Israel, M. A.; Emre, N.; Marsala, S.; Marsala, M.; Gage, F. H.; Goldstein, L. S.; Carson, C. T., Cell-surface marker signatures for the isolation of neural stem cells, glia and neurons derived from human pluripotent stem cells. *PLoS One* **2011**, 6, (3), e17540.
31. Raj, B.; Irimia, M.; Braunschweig, U.; Sterne-Weiler, T.; O'Hanlon, D.; Lin, Z. Y.; Chen, G. I.; Easton, L. E.; Ule, J.; Gingras, A. C.; Eyras, E.; Blencowe, B. J., A global regulatory mechanism for activating an exon network required for neurogenesis. *Mol Cell* **2014**, 56, (1), 90-103.
32. Wang, D. B.; Kinoshita, Y.; Kinoshita, C.; Uo, T.; Sopher, B. L.; Cudaback, E.; Keene, C. D.; Bilousova, T.; Gyls, K.; Case, A.; Jayadev, S.; Wang, H. G.; Garden, G. A.; Morrison, R. S., Loss of endophilin-B1 exacerbates Alzheimer's disease pathology. *Brain* **2015**, 138, (Pt 7), 2005-19.
33. Bedogni, F.; Hodge, R. D.; Elsen, G. E.; Nelson, B. R.; Daza, R. A.; Beyer, R. P.; Bammler, T. K.; Rubenstein, J. L.; Hevner, R. F., Tbr1 regulates regional and laminar identity of postmitotic neurons in developing neocortex. *Proc Natl Acad Sci U S A* **2010**, 107, (29), 13129-34.
34. Li, P. A.; Hou, X.; Hao, S., Mitochondrial biogenesis in neurodegeneration. *J Neurosci Res* **2017**, 95, (10), 2025-2029.
35. Grimm, A.; Eckert, A., Brain aging and neurodegeneration: from a mitochondrial point of view. *J Neurochem* **2017**, 143, (4), 418-431.
36. Lee, J. S.; Yoon, Y. G.; Yoo, S. H.; Jeong, N. Y.; Jeong, S. H.; Lee, S. Y.; Jung, D. I.; Jeong, S. Y.; Yoo, Y. H., Histone deacetylase inhibitors induce mitochondrial elongation. *J Cell Physiol* **2012**, 227, (7), 2856-69.
37. Schrepfer, E.; Scorrano, L., Mitofusins, from Mitochondria to Metabolism. *Mol Cell* **2016**, 61, (5), 683-694.
38. Morris, E. J.; Geller, H. M., Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity. *J Cell Biol* **1996**, 134, (3), 757-70.
39. Uo, T.; Veenstra, T. D.; Morrison, R. S., Histone deacetylase inhibitors prevent p53-dependent and p53-independent Bax-mediated neuronal apoptosis through two distinct mechanisms. *J Neurosci* **2009**, 29, (9), 2824-32.
40. Pich, S.; Bach, D.; Briones, P.; Liesa, M.; Camps, M.; Testar, X.; Palacin, M.; Zorzano, A., The Charcot-Marie-Tooth type 2A gene product, Mfn2, up-regulates fuel oxidation through expression of OXPHOS system. *Hum Mol Genet* **2005**, 14, (11), 1405-15.
41. Fang, D.; Yan, S.; Yu, Q.; Chen, D.; Yan, S. S., Mfn2 is Required for Mitochondrial Development and Synapse Formation in Human Induced Pluripotent Stem Cells/hiPSC Derived Cortical Neurons. *Sci Rep* **2016**, 6, 31462.
42. Valenti, D.; Rossi, L.; Marzulli, D.; Bellomo, F.; De Rasmio, D.; Signorile, A.; Vacca, R. A., Inhibition of Drp1-mediated mitochondrial fission improves mitochondrial dynamics and bioenergetics

- stimulating neurogenesis in hippocampal progenitor cells from a Down syndrome mouse model. *Biochim Biophys Acta Mol Basis Dis* **2017**, 1863, (12), 3117-3127. 730
43. Shukla, S.; Tekwani, B. L., Histone Deacetylases Inhibitors in Neurodegenerative Diseases, 731
Neuroprotection and Neuronal Differentiation. *Front Pharmacol* **2020**, 11, 537. 732
44. Schmidt, M.; Sachse, C.; Richter, W.; Xu, C.; Fandrich, M.; Grigorieff, N., Comparison of Alzheimer 733
Aβ(1-40) and Aβ(1-42) amyloid fibrils reveals similar protofilament structures. *Proc Natl Acad Sci U S A* **2009**, 106, (47), 19813-8. 734
45. Brownjohn, P. W.; Smith, J.; Portelius, E.; Serneels, L.; Kvartsberg, H.; De Strooper, B.; Blennow, K.; 735
Zetterberg, H.; Livesey, F. J., Phenotypic Screening Identifies Modulators of Amyloid Precursor 736
Protein Processing in Human Stem Cell Models of Alzheimer's Disease. *Stem Cell Reports* **2017**, 8, 737
(4), 870-882. 738
46. van der Kant, R.; Langness, V. F.; Herrera, C. M.; Williams, D. A.; Fong, L. K.; Leestemaker, Y.; 739
Steenvoorden, E.; Ryneerson, K. D.; Brouwers, J. F.; Helms, J. B.; Ovaa, H.; Giera, M.; Wagner, S. L.; 740
Bang, A. G.; Goldstein, L. S. B., Cholesterol Metabolism Is a Druggable Axis that Independently 741
Regulates Tau and Amyloid-beta in iPSC-Derived Alzheimer's Disease Neurons. *Cell Stem Cell* **2019**, 742
24, (3), 363-375 e9. 743
47. Rovelet-Lecrux, A.; Hannequin, D.; Raux, G.; Le Meur, N.; Laquerriere, A.; Vital, A.; Dumanchin, C.; 744
Feuillet, S.; Brice, A.; Vercelletto, M.; Dubas, F.; Frebourg, T.; Campion, D., APP locus duplication 745
causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. *Nat 746
Genet* **2006**, 38, (1), 24-6. 747
48. D'Mello, S. R., Regulation of Central Nervous System Development by Class I Histone Deacetylases. 748
Dev Neurosci **2019**, 41, (3-4), 149-165. 749
49. MacDonald, J. L.; Gin, C. S.; Roskams, A. J., Stage-specific induction of DNA methyltransferases in 750
olfactory receptor neuron development. *Dev Biol* **2005**, 288, (2), 461-73. 751
50. Jawerka, M.; Colak, D.; Dimou, L.; Spiller, C.; Lagger, S.; Montgomery, R. L.; Olson, E. N.; Wurst, W.; 752
Gottlicher, M.; Gotz, M., The specific role of histone deacetylase 2 in adult neurogenesis. *Neuron 753
Glia Biol* **2010**, 6, (2), 93-107. 754
51. Gan, Y.; Li, Y.; Long, Z.; Lee, A. R.; Xie, N.; Lovnicki, J. M.; Tang, Y.; Chen, X.; Huang, J.; Dong, X., Roles 755
of Alternative RNA Splicing of the Bif-1 Gene by SRRM4 During the Development of Treatment- 756
induced Neuroendocrine Prostate Cancer. *EBioMedicine* **2018**, 31, 267-275. 757
52. Karbowski, M.; Jeong, S. Y.; Youle, R. J., Endophilin B1 is required for the maintenance of 758
mitochondrial morphology. *J Cell Biol* **2004**, 166, (7), 1027-39. 759
53. Cho, S. G.; Xiao, X.; Wang, S.; Gao, H.; Rafikov, R.; Black, S.; Huang, S.; Ding, H. F.; Yoon, Y.; Kirken, R. 760
A.; Yin, X. M.; Wang, H. G.; Dong, Z., Bif-1 Interacts with Prohibitin-2 to Regulate Mitochondrial 761
Inner Membrane during Cell Stress and Apoptosis. *J Am Soc Nephrol* **2019**, 30, (7), 1174-1191. 762
54. Agostini, M.; Romeo, F.; Inoue, S.; Niklison-Chirou, M. V.; Elia, A. J.; Dinsdale, D.; Morone, N.; 763
Knight, R. A.; Mak, T. W.; Melino, G., Metabolic reprogramming during neuronal differentiation. *Cell 764
Death Differ* **2016**, 23, (9), 1502-14. 765
55. Zheng, X.; Boyer, L.; Jin, M.; Mertens, J.; Kim, Y.; Ma, L.; Ma, L.; Hamm, M.; Gage, F. H.; Hunter, T., 766
Metabolic reprogramming during neuronal differentiation from aerobic glycolysis to neuronal 767
oxidative phosphorylation. *Elife* **2016**, 5. 768

56. Lkhagva, B.; Kao, Y. H.; Lee, T. I.; Lee, T. W.; Cheng, W. L.; Chen, Y. J., Activation of Class I histone deacetylases contributes to mitochondrial dysfunction in cardiomyocytes with altered complex activities. *Epigenetics* **2018**, 13, (4), 376-385.
57. Levy, S.; Sutton, G.; Ng, P. C.; Feuk, L.; Halpern, A. L.; Walenz, B. P.; Axelrod, N.; Huang, J.; Kirkness, E. F.; Denisov, G.; Lin, Y.; MacDonald, J. R.; Pang, A. W.; Shago, M.; Stockwell, T. B.; Tsiamouri, A.; Bafna, V.; Bansal, V.; Kravitz, S. A.; Busam, D. A.; Beeson, K. Y.; McIntosh, T. C.; Remington, K. A.; Abril, J. F.; Gill, J.; Borman, J.; Rogers, Y. H.; Frazier, M. E.; Scherer, S. W.; Strausberg, R. L.; Venter, J. C., The diploid genome sequence of an individual human. *PLoS Biol* **2007**, 5, (10), e254.
58. Miyaoka, Y.; Chan, A. H.; Judge, L. M.; Yoo, J.; Huang, M.; Nguyen, T. D.; Lizarraga, P. P.; So, P. L.; Conklin, B. R., Isolation of single-base genome-edited human iPS cells without antibiotic selection. *Nat Methods* **2014**, 11, (3), 291-3.
59. Chambers, S. M.; Fasano, C. A.; Papapetrou, E. P.; Tomishima, M.; Sadelain, M.; Studer, L., Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. *Nat Biotechnol* **2009**, 27, (3), 275-80.
60. Shi, Y.; Kirwan, P.; Smith, J.; Robinson, H. P.; Livesey, F. J., Human cerebral cortex development from pluripotent stem cells to functional excitatory synapses. *Nat Neurosci* **2012**, 15, (3), 477-86, S1.